CRL

Charles River Laboratories Acquires Retrogenix

Retrieved on: 
Wednesday, March 31, 2021
Research, Medical devices, Genetics, Stem cells, Biotechnology, Health, Pharmaceutical, General Health, Science, Life sciences, Contract research organizations, Articles, Retrogenix, Microarray, Charles River Laboratories, CRL, Health sciences

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired Retrogenix Limited, an early-stage contract research organization (CRO) providing specialized bioanalytical services utilizing its proprietary cell microarray technology.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired Retrogenix Limited, an early-stage contract research organization (CRO) providing specialized bioanalytical services utilizing its proprietary cell microarray technology.
  • The acquisition of Retrogenix enhances Charles Rivers scientific expertise with additional large molecule and cell therapy discovery capabilities.
  • James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories, commented, The acquisition of Retrogenix strategically expands Charles Rivers existing discovery capabilities by adding a proprietary cell microarray technology to accelerate target identification and provide preclinical safety assurance for novel therapies.
  • We are pleased to welcome Retrogenix and its talented staff to the Charles River family.

Charles River Laboratories to Present at Barclays Global Healthcare Conference

Retrieved on: 
Monday, March 8, 2021
Biotechnology, General Health, Medical devices, Health, Pharmaceutical, Health sciences, Life sciences, Pharmacy, Charles River Laboratories, CRL, BIOTEC, Pharmaceutical industry, Articles

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the Barclays Global Healthcare Conference on Wednesday, March 10th, at 10:20 a.m.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the Barclays Global Healthcare Conference on Wednesday, March 10th, at 10:20 a.m.
  • Management will present an overview of Charles Rivers strategic focus and business developments.
  • A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com .
  • Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.

Aquestive Therapeutics Reaffirms Near-Term NDA Resubmission for Libervant™ (diazepam) Buccal Film Following FDA Feedback

Retrieved on: 
Thursday, February 25, 2021
Intellectual property law, Brand management, Brands, Product management, Trademark, Food and Drug Administration, CRL, Marketing, Market economics)

We have a clear path to resubmitting our NDA for Libervant and expect to do so around the end of the second quarter of 2021.

Key Points: 
  • We have a clear path to resubmitting our NDA for Libervant and expect to do so around the end of the second quarter of 2021.
  • Aquestive is aligned with the FDAs expectations and will include the requested information in its upcoming resubmission of the NDA for Libervant.
  • Aquestive received a Complete Response Letter (CRL) from the FDA on September 25, 2020 and subsequently completed a Type A meeting with the FDA in November of 2020.
  • PharmFilm, Sympazan and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All other registered trademarks referenced herein are the property of their respective owners.

Charles River Laboratories Schedules Fourth-Quarter 2020 Earnings and 2021 Guidance Release and Conference Call

Retrieved on: 
Wednesday, January 20, 2021
Health, Medical devices, General Health, Research, Science, Pharmaceutical, Biotechnology, Finance, Money, Economy, Charles River Laboratories, New York Stock Exchange, Investor, CRL

Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2020 financial results and provide 2021 guidance on Wednesday, February 17th, before the market opens.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2020 financial results and provide 2021 guidance on Wednesday, February 17th, before the market opens.
  • A conference call has been scheduled to discuss this information on Wednesday, February 17th, at 8:30 a.m.
  • Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com .
  • Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 11, 2021
Medical devices, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Charles River Laboratories, CRL, New York Stock Exchange, BIOTEC, Articles, Life sciences, New York City

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12th, at 10:00 a.m. EST.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12th, at 10:00 a.m. EST.
  • Management will present an overview of Charles Rivers strategic focus, business developments, and recent trends.
  • A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com .
  • Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.

Charles River Laboratories Acquires Distributed Bio

Retrieved on: 
Monday, January 4, 2021
Biotechnology, General Health, Medical devices, Health, Pharmaceutical, Contract research organizations, James C. Foster, Charles River Laboratories, CRL, Discovery, Life sciences, Articles, Industry economics)

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it acquired of Distributed Bio, Inc. on December 31, 2020.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it acquired of Distributed Bio, Inc. on December 31, 2020.
  • The acquisition of Distributed Bio expands Charles Rivers scientific capabilities with an innovative, large-molecule discovery platform.
  • James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories, commented, The addition of Distributed Bios next-generation antibody discovery capabilities further enhances Charles Rivers unique ability to serve as a single-source partner to support our clients early-stage research.
  • We are pleased to welcome Distributed Bio to the Charles River family.

Charles River Laboratories to Present at Upcoming Investor Conferences

Retrieved on: 
Monday, November 9, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Medical devices, Evercore, Charles River Laboratories, CRL, Finance, Articles, Companies

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at three upcoming investor conferences, including:

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at three upcoming investor conferences, including:
    Credit Suisse 29th Annual Virtual Healthcare Conference on Tuesday, November 10th, at 10:15 a.m. EST;
    Jefferies Virtual London Healthcare Conference on Wednesday, November 18th, at 2:40 p.m. GMT (9:40 a.m. EST); and
    Evercore ISI 3rd Annual HealthCONx Conference on Wednesday, December 2nd, at 9:40 a.m. EST.
  • Management will present an overview of Charles Rivers strategic focus and business developments.
  • A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com .
  • Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.

Clinical Reference Laboratory to Market Most Cost-Effective, Gold-Standard Self-Collected COVID-19 Saliva Test Directly to Consumers

Retrieved on: 
Monday, November 9, 2020
Natural sciences, Biotechnology, Laboratory techniques, Molecular biology, Biology, Life sciences, Reverse transcription polymerase chain reaction, Polymerase chain reaction, Coronavirus disease, CRL

LENEXA, Kan., Nov. 9, 2020 /PRNewswire/ --Today, Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S., announced that it has begun selling its best-in-class CRL Rapid Response saliva-based COVID-19 RT-PCR test directly to consumers.

Key Points: 
  • LENEXA, Kan., Nov. 9, 2020 /PRNewswire/ --Today, Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S., announced that it has begun selling its best-in-class CRL Rapid Response saliva-based COVID-19 RT-PCR test directly to consumers.
  • The CRL Rapid Response saliva-based COVID-19 RT-PCR test is for symptomatic individuals or those who believe they may have been exposed.
  • With CRL Rapid Response, saliva is collected in a DNA Genotek OMNIgene ORAL (OM-505) saliva collection device, specifically designed for self-collection, stabilization, storage and shipment to the laboratory.
  • Clinical Reference Laboratory is one of the largest privately held clinical testing laboratories in the U.S., performing hundreds of thousands of tests every day for clients large and small.

Charles River Laboratories Schedules Third-Quarter 2020 Earnings Release and Conference Call

Retrieved on: 
Tuesday, October 13, 2020
Professional services, Health, Medical devices, Finance, General Health, Pharmaceutical, Biotechnology, Articles, Finance, Money, Charles River Laboratories, New York Stock Exchange, CRL, Pharmaceutical industry, Investor

Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2020 financial results on Thursday, October 29th, before the market opens.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2020 financial results on Thursday, October 29th, before the market opens.
  • A conference call has been scheduled to discuss this information on Thursday, October 29th, at 9:30 a.m.
  • Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com .
  • Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.

OmniTRAX’s Chicago Rail Link and Calumet Area Industrial Commission to Promote Rail-Ready Sites

Retrieved on: 
Wednesday, August 5, 2020
Other Policy Issues, Other Manufacturing, Other Government, Engineering, Logistics, Supply chain management, Manufacturing, Public policy, Government, Other Construction & Property, Commercial Building & Real Estate, Construction & Property, Other Transport, Other Energy, Urban planning, Trucking, Rail, Transport, Energy, Other Natural Resources, Mining, Minerals, White House, Federal Government, Natural Resources, Rail transportation in the United States, OmniTRAX, Rail transport by country, Chicago Rail Link, CRL, Chicago, Calumet, OmniTRAX, Inc., The Broe Group

OmniTRAX , one of the fastest growing railroads in North America and an affiliate of The Broe Group, is working with the Calumet Area Industrial Commission (CAIC) to launch its Rail-Ready Sites program at the Chicago Rail Link (CRL).

Key Points: 
  • OmniTRAX , one of the fastest growing railroads in North America and an affiliate of The Broe Group, is working with the Calumet Area Industrial Commission (CAIC) to launch its Rail-Ready Sites program at the Chicago Rail Link (CRL).
  • To review these sites and learn more about how OmniTRAX helps companies locate on rail-served properties, visit this link .
  • The southside of Chicago is undergoing a major industrial renaissance and the CRL is playing a central role for shippers and receivers.
  • The mission of the organization is to promote industrial retention and development within the area.